Novo Nordisk A/S vs United States Natural Gas Fund — how do they compare? Novo Nordisk A/S trades at $46.17 (market cap $207.85B), while United States Natural Gas Fund trades at $10.21. The key difference: Novo Nordisk A/S pays a 3.81% dividend while United States Natural Gas Fund pays none, and Novo Nordisk A/S is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| NVO | UNG | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Commodities - Energy |
52-Week High | $63.98 | $16.90 |
52-Week Low | $35.29 | $9.63 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
UNG, tracking U.S. natural gas futures, trades at $10.24 with a 0.99% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. Recent news highlights steady natural gas prices amid weather-driven demand shifts and geopolitical tensions. The fund lacks traditional company fundamentals as it is an ETF, with financial ratios unavailable.
The outlook is cautious due to bearish technicals and volatile commodity exposure. Opportunities exist if natural gas demand surges from weather or LNG exports, but risks include price swings from storage levels and production changes. Investors should weigh this as a speculative play on energy markets.
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →